Understand the source comparison
Comparison: Semax vs Semax Amidate vs Dihexa
Structural Class Heptapeptide (ACTH analog) Amidated heptapeptide Small-molecule peptidomimetic Semax amidate offers best stability-to-activity ratio for intranasal protocols Half-Life (Rodent Models) 25–35 minutes 90–120 minutes 4–6 hours (oral) Dihexa's oral
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Structural Class
- Heptapeptide (ACTH analog)
- Amidated heptapeptide
- Small-molecule peptidomimetic
- Semax amidate offers best stability-to-activity ratio for intranasal protocols
- Half-Life (Rodent Models)
- 25–35 minutes
- 90–120 minutes
- 4–6 hours (oral)
- Dihexa's oral bioavailability simplifies dosing but limits acute intervention studies
- Primary Mechanism
- BDNF upregulation via MC4R
- HGF receptor agonism → PI3K/Akt
- Semax variants modulate transcription; dihexa drives structural plasticity
- Route of Administration
- Intranasal, subcutaneous
- Oral, intraperitoneal
- Intranasal semax bypasses first-pass metabolism but requires consistent technique
- Typical Research Dose
- 0.3–1.0 mg/kg
- 0.2–0.8 mg/kg
- 0.05–0.5 mg/kg
- Amidate's extended half-life allows 20–30% dose reduction vs free acid
- Synaptic Structural Changes
- Minimal
- Significant (dendritic spine formation)
- Dihexa is the only compound that produces measurable morphological changes at standard doses